| Metric | Value (₹ Cr) | vs Q3 FY25 |
|---|---|---|
| Revenue | 345.29 | 7.0% |
| Total Income | 352.26 | 8.3% |
| Expenditure | 316.22 | 11.7% |
| PBT | 36.04 | 14.9% |
| Net Profit | 29.23 | 7.1% |
| OPM | 18.04% | 15.70pp |
| NPM | 8.30% | 1.37pp |
| EPS | 5.69 | 6.9% |
Metropolis Healthcare Reports Normalised PAT Growth of 26% for Full Year FY2024-25 and 24% in Q4FY25
13 May 2025 · 13 May 2025, 11:30 pm
Summary
Metropolis Healthcare, India's second-largest pathology laboratory chain, announced its audited consolidated financial results for the quarter ended March 31, 2025 (FY25 and Q4FY25). The company reported a Normalised PAT Growth of 26% for the full year and 24% in Q4FY25. Metropolis achieved double-digit revenue growth at 12% YoY for FY2024-25 and 10% YoY in Q4FY25, driven by consistent volume expansion. TruHealth and Specialty diagnostics led as the fastest-growing segments.
Key Highlights
- 1
Metropolis records revenue of INR 1,331 Crore in FY25 and INR 345 Crore in Q4FY25.
- 2
Patient volume grew by 6% YoY and Test Volume grew by 7% in FY25.
- 3
B2C revenues saw a robust 17% YoY growth in FY25 and 14% YoY in Q4FY25.
- 4
B2B revenue grew 12% YoY in FY25 and 10% YoY in Q4FY25.
- 5
TruHealth revenue grew 24% YoY with a strong Q4 exit contributing 19% to total revenue.
- 6
Specialty diagnostics also maintained momentum, growing 13% YoY in FY25.
- 7
Revenue growth contribution from Tier III cities stood at 18% in FY25.
- 8
Expanded to 750+ towns in FY25 with addition of 29 new labs and 400 centres in FY25.
Management Comments
Ameera Shah
Executive Chairperson & Whole-time Director, Metropolis Healthcare Limited
Over the past four years, Metropolis has built a resilient, future-ready organization through strategic investments in laboratories, network expansion, brand, technology, and talent. Despite a challenging environment, we have strengthened our scientific leadership, enhanced customer engagement, and driving operational excellence. We are confident that our recent acquisitions — Core Diagnostics, Scientific Pathology, and Dr. Ahuja’s Pathology & Imaging Centre — will generate strong returns and fuel the next phase of growth. These acquisitions reinforce our leadership in specialty testing, expand our B2C footprint, and strengthen our regional presence in North India. With a robust foundation, a differentiated portfolio in high-growth segments, and a deeper penetration across key regions, Metropolis is well positioned to capitalize on emerging opportunities and drive long-term stakeholder value.
Surendran Chemmenkotil
Chief Executive Officer, Metropolis Healthcare Limited
FY25 has been a pivotal year in our journey toward becoming a more consumer-centric and digitally enabled diagnostics brand. Our growth was fuelled by rising demand for preventive and specialized testing, enabled by focused execution, stronger clinician engagement, and meaningful innovation. We introduced industry-first cancer screening panels and tools, along with Al-powered diagnostics to enhance accuracy and enable early detection. Our proprietary engine, MetAdvisor, uses historical data to deliver personalized, science-led test recommendations—boosting TruHealth performance. As we look ahead, our focus is on strengthening our presence in key cities, expanding digital access, and advancing evidence-based preventive care. With science at the heart of our efforts, we aim to make quality diagnostics more accessible, reliable, and impactful for the communities we serve.
Informational and educational content only. Not investment advice.